69 related articles for article (PubMed ID: 1332102)
1. Thyroid functions in patients treated with interleukin-2 and lymphokine-activated killer cells.
Kung AW; Lai CL; Wong KL; Tam CF
Q J Med; 1992 Jan; 82(297):33-42. PubMed ID: 1332102
[TBL] [Abstract][Full Text] [Related]
2. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment.
Weijl NI; Van der Harst D; Brand A; Kooy Y; Van Luxemburg S; Schroder J; Lentjes E; Van Rood JJ; Cleton FJ; Osanto S
J Clin Oncol; 1993 Jul; 11(7):1376-83. PubMed ID: 8315436
[TBL] [Abstract][Full Text] [Related]
3. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.
Atkins MB; Mier JW; Parkinson DR; Gould JA; Berkman EM; Kaplan MM
N Engl J Med; 1988 Jun; 318(24):1557-63. PubMed ID: 3259674
[TBL] [Abstract][Full Text] [Related]
4. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
[TBL] [Abstract][Full Text] [Related]
5. Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients.
Sartore-Bianchi A; Soriani A; Mattioni R; Vaglio A; Buzio C; Porta C
Oncol Rep; 2004 Oct; 12(4):855-9. PubMed ID: 15375512
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of insulin autoantibodies following interleukin-2 and lymphokine activated killer cell therapy.
Bergstrom RW; Atkins MB; Mier JW; Palmer JP
J Clin Lab Immunol; 1990 Apr; 31(4):189-93. PubMed ID: 1967063
[TBL] [Abstract][Full Text] [Related]
8. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.
Hermann GG; Geertsen PF; von der Maase H; Steven K; Andersen C; Hald T; Zeuthen J
Cancer Res; 1992 Feb; 52(3):726-33. PubMed ID: 1732060
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of autoimmune hypothyroidism induced by lymphokine-activated killer (LAK) cell therapy: in vitro inhibition of human thyroid function by interleukin-2 in the presence of autologous intrathyroidal lymphocytes.
Sato K; Yamazaki K; Shizume K; Yamakawa Y; Satoh T; Demura H; Kanaji Y; Obara T; Fujimoto Y; Aiba M
Thyroid; 1993; 3(3):179-88. PubMed ID: 8257856
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
[TBL] [Abstract][Full Text] [Related]
11. Locoregional immunochemotherapy in hepatocellular carcinoma.
Kountouras J; Boura P; Kouklakis G
Hepatogastroenterology; 2002; 49(46):1109-12. PubMed ID: 12143214
[TBL] [Abstract][Full Text] [Related]
12. Depressed lymphokine-activated killer activity and analysis of the precursor cells in peripheral blood of patients with hepatocellular carcinoma.
Shirai M; Watanabe S; Nishioka M
Hepatogastroenterology; 1990 Oct; 37(5):465-8. PubMed ID: 2174825
[TBL] [Abstract][Full Text] [Related]
13. Measurement of serum total thyroxine, triiodothyronine, free thyroxine, and thyrotropin concentrations for diagnosis of hypothyroidism in dogs.
Peterson ME; Melián C; Nichols R
J Am Vet Med Assoc; 1997 Dec; 211(11):1396-402. PubMed ID: 9394888
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and pattern of sick euthyroid syndrome in acute and chronic non-thyroidal illness--its relationship with severity and outcome of the disorder.
Zargar AH; Ganie MA; Masoodi SR; Laway BA; Bashir MI; Wani AI; Salahuddin M
J Assoc Physicians India; 2004 Jan; 52():27-31. PubMed ID: 15633715
[TBL] [Abstract][Full Text] [Related]
15. Effects of interferon-gamma therapy on thyroid function, T-lymphocyte subpopulations and induction of autoantibodies.
Kung AW; Jones BM; Lai CL
J Clin Endocrinol Metab; 1990 Nov; 71(5):1230-4. PubMed ID: 2121769
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma.
Onishi S; Saibara T; Fujikawa M; Sakaeda H; Matsuura Y; Matsunaga Y; Yamamoto Y
Hepatology; 1989 Sep; 10(3):349-53. PubMed ID: 2474481
[TBL] [Abstract][Full Text] [Related]
17. [Thyroid function abnormalities during interferon therapy].
Tsukada K; Nomura T; Higashi K; Takeuchi T
Nihon Rinsho; 1994 Jul; 52(7):1895-900. PubMed ID: 8078204
[TBL] [Abstract][Full Text] [Related]
18. Crescentic IgA glomerulonephritis following interleukin-2 therapy for hepatocellular carcinoma of the liver.
Chan TM; Cheng IK; Wong KL; Chan KW; Lai CL
Am J Nephrol; 1991; 11(6):493-6. PubMed ID: 1668057
[TBL] [Abstract][Full Text] [Related]
19. Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha.
Jacobs EL; Clare-Salzler MJ; Chopra IJ; Figlin RA
J Immunother (1991); 1991 Dec; 10(6):448-55. PubMed ID: 1768679
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone.
Kawata A; Une Y; Hosokawa M; Wakizaka Y; Namieno T; Uchino J; Kobayashi H
Am J Clin Oncol; 1995 Jun; 18(3):257-62. PubMed ID: 7747715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
